BioAtla Management

Management criteria checks 2/4

BioAtla's CEO is Jay Short, appointed in Mar 2007, has a tenure of 17.67 years. total yearly compensation is $3.30M, comprised of 21.6% salary and 78.4% bonuses, including company stock and options. directly owns 5.56% of the company’s shares, worth $4.03M. The average tenure of the management team and the board of directors is 4.6 years and 4.3 years respectively.

Key information

Jay Short

Chief executive officer

US$3.3m

Total compensation

CEO salary percentage	21.6%
CEO tenure	17.7yrs
CEO ownership	5.6%
Management average tenure	4.6yrs
Board average tenure	4.3yrs

Recent management updates

Recent updates

BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy

Oct 08

CEO Compensation Analysis

How has Jay Short's remuneration changed compared to BioAtla's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	-US$82m
Jun 30 2024	n/a	n/a	-US$105m
Mar 31 2024	n/a	n/a	-US$119m
Dec 31 2023	US$3m	US$713k	-US$123m
Sep 30 2023	n/a	n/a	-US$124m
Jun 30 2023	n/a	n/a	-US$117m
Mar 31 2023	n/a	n/a	-US$110m
Dec 31 2022	US$3m	US$686k	-US$106m
Sep 30 2022	n/a	n/a	-US$102m
Jun 30 2022	n/a	n/a	-US$99m
Mar 31 2022	n/a	n/a	-US$101m
Dec 31 2021	US$1m	US$660k	-US$95m
Sep 30 2021	n/a	n/a	-US$79m
Jun 30 2021	n/a	n/a	-US$68m
Mar 31 2021	n/a	n/a	-US$44m
Dec 31 2020	US$12m	US$636k	-US$27m
Sep 30 2020	n/a	n/a	-US$22m
Dec 31 2019	US$991k	US$610k	-US$29m

Compensation vs Market: Jay's total compensation ($USD3.30M) is above average for companies of similar size in the US market ($USD652.28K).

Compensation vs Earnings: Jay's compensation has increased whilst the company is unprofitable.

CEO

Jay Short (66 yo)

17.7yrs

Tenure

US$3,301,346

Compensation

Dr. Jay M. Short, Ph D., serves as the Chairman and Chief Executive Officer of BioAtla, LLC. since March 2007.He is the Co-Founder of BioAtla, Inc. in March 2007. Dr. Short serves as an Advisor at SG Biof...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jay Short	Co-Founder	17.7yrs	US$3.30m	5.56% $ 4.0m
Richard Waldron	Senior VP & CFO	11yrs	US$1.24m	0.55% $ 400.3k
Eric Sievers	Chief Medical Officer	5.4yrs	US$1.32m	0.17% $ 123.5k
Christian Vasquez	Chief Accounting Officer	9yrs	US$605.41k	0.24% $ 173.5k
Susie Melody	Senior Vice President of Human Resources	no data	no data	no data
Cathy Chang	Senior Vice President of Research & Development	3.8yrs	no data	no data
Gerhard Frey	Senior Vice President of Technology Development	1.8yrs	no data	no data
Monica Sullivan	Senior Vice President of Intellectual Property & Contracts	2.7yrs	no data	no data
Sheri Lydick	Chief Commercial Officer	3yrs	no data	no data
Lisa Pelton	Accounting Manager	no data	no data	no data

4.6yrs

Average Tenure

63yo

Average Age

Experienced Management: BCAB's management team is considered experienced (4.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Jay Short	Co-Founder	17.7yrs	US$3.30m	5.56% $ 4.0m
Lawrence Steinman	Independent Director	4.3yrs	US$161.19k	0.080% $ 57.7k
Sylvia McBrinn	Independent Director	3.4yrs	US$164.57k	0.040% $ 28.7k
Mary Gray	Independent Director	3.9yrs	US$180.44k	0.077% $ 56.1k
James Allison	Advisor	7yrs	no data	no data
Edward Williams	Independent Director	2.9yrs	US$168.94k	0.042% $ 30.3k
Padmanee Sharma	Advisor	7yrs	no data	no data
Scott Smith	Director	4.3yrs	US$1.77m	0.55% $ 400.3k
Lawrence Fong	Scientific Advisor	6.3yrs	no data	no data
Susan Moran	Independent Director	3.9yrs	US$158.19k	0.025% $ 18.5k

4.3yrs

Average Tenure

68yo

Average Age

Experienced Board: BCAB's board of directors are considered experienced (4.3 years average tenure).

BioAtla Management

Management criteria checks 2/4

Key information

Recent management updates

BioAtla, Inc., Annual General Meeting, Jun 13, 2024

Co-Founder recently bought US$107k worth of stock

Co-Founder recently bought US$101k worth of stock

High number of new and inexperienced directors

Co-Founder recently bought US$207k worth of stock

VP of Finance recently bought US$151k worth of stock

Recent updates

BioAtla, Inc. to Report Q3, 2024 Results on Nov 07, 2024

BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy

Bioatla, Inc. Presents Promising Phase 2 Trial Data for Ozuriftamab Vedotin At Esmo Annual Meeting, Highlighting Efficacy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

BioAtla, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Bioatla Granted FDA Fast Track Designation for Ozuriftamab Vedotin (CAB-ROR2-ADC) for Treatment of Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

We're A Little Worried About BioAtla's (NASDAQ:BCAB) Cash Burn Rate

BioAtla, Inc.(NasdaqGM:BCAB) dropped from Russell Small Cap Comp Value Index

BioAtla, Inc. Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

New major risk - Financial position

BioAtla, Inc. to Report Q1, 2024 Results on May 14, 2024

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors

BioAtla: A Buried ADC Concern Gets Some New Life In 2024

BioAtla, Inc., Annual General Meeting, Jun 13, 2024

BioAtla, Inc. to Report Q4, 2023 Results on Mar 26, 2024

New minor risk - Shareholder dilution

Will BioAtla (NASDAQ:BCAB) Spend Its Cash Wisely?

Upendar Golla Files Putative Class Action Lawsuit against Bioatla, Inc

Upendar Golla Files Putative Class Action Lawsuit against Bioatla, Inc

Co-Founder recently bought US$107k worth of stock

Bioatla Hosting Virtual R&D Day to Highlight Ba3071 Cab-Ctla-4 Phase 1 Data in Multiple Solid Tumor Types

BioAtla, Inc. Presents Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event

Is BioAtla (NASDAQ:BCAB) In A Good Position To Deliver On Growth Plans?

BioAtla, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New minor risk - Share price stability

Price target decreased by 9.4% to US$15.25

Consensus EPS estimates fall by 13%

BioAtla, Inc. to Report Q2, 2023 Results on Aug 01, 2023

We Think BioAtla (NASDAQ:BCAB) Needs To Drive Business Growth Carefully

BioAtla, Inc. to Report Q1, 2023 Results on May 11, 2023

Co-Founder recently bought US$101k worth of stock

Price target decreased by 8.2% to US$24.00

Price target decreased by 8.5% to US$24.71

Will BioAtla (NASDAQ:BCAB) Spend Its Cash Wisely?

High number of new and inexperienced directors

BioAtla (NASDAQ:BCAB) Is In A Good Position To Deliver On Growth Plans

BioAtla: Back From The Dead

Price target decreased to US$27.00

BioAtla: Promising Signal In NSCLC, But Concerns Remain

Co-Founder recently bought US$207k worth of stock

BioAtla reports Q2 results

BioAtla, Inc. to Report Q2, 2022 Results on Aug 09, 2022

BioAtla, Inc.(NasdaqGM:BCAB) dropped from Russell 2000 Growth Index

VP of Finance recently bought US$151k worth of stock

Bioatla, Inc. Announces Executive Changes, Effective June 16, 2022

We're Keeping An Eye On BioAtla's (NASDAQ:BCAB) Cash Burn Rate

Price target decreased to US$41.17

High number of new directors

BioAtla, Inc., Annual General Meeting, Jun 16, 2022

BioAtla, Inc. to Report Q1, 2022 Results on May 04, 2022

Consensus forecasts updated

Price target decreased to US$44.40

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$59.60

Companies Like BioAtla (NASDAQ:BCAB) Are In A Position To Invest In Growth

Chief Financial Officer recently sold US$333k worth of stock

Co-Founder notifies of intention to sell stock

Co-Founder recently sold US$1.2m worth of stock

Co-Founder notifies of intention to sell stock

Third quarter 2021 earnings released: US$0.65 loss per share (vs US$1.87 loss in 3Q 2020)

Independent Director notifies of intention to sell stock

President & Director recently sold US$90k worth of stock

President & Director recently sold US$1.3m worth of stock

Independent Director notifies of intention to sell stock

Consensus revenue estimates fall to US$17.6m

BioAtla (NASDAQ:BCAB) Is In A Good Position To Deliver On Growth Plans

BioAtla, Inc.(NasdaqGM:BCAB) dropped from Russell 3000E Value Index

Co-Founder recently sold US$5.0m worth of stock

Are Insiders Buying BioAtla, Inc. (NASDAQ:BCAB) Stock?